

# SCIENTIFIC REPORTS



OPEN

## Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells

Received: 08 November 2016

Accepted: 26 January 2017

Published: 06 March 2017


S. Yadavalli<sup>1</sup>, S. Jayaram<sup>1,2</sup>, S. S. Manda<sup>1,3</sup>, A. K. Madugundu<sup>1,3</sup>, D. S. Nayakanti<sup>1</sup>, T. Z. Tan<sup>4</sup>, R. Bhat<sup>5</sup>, A. Rangarajan<sup>5</sup>, A. Chatterjee<sup>1,6</sup>, H. Gowda<sup>1,6</sup>, J. P. Thiery<sup>4,7,8,9</sup> & P. Kumar<sup>1</sup>

Circulating tumor cells (CTCs) play a crucial role in cancer dissemination and provide a promising source of blood-based markers. Understanding the spectrum of transcriptional profiles of CTCs and their corresponding regulatory mechanisms will allow for a more robust analysis of CTC phenotypes. The current challenge in CTC research is the acquisition of useful clinical information from the multitude of high-throughput studies. To gain a deeper understanding of CTC heterogeneity and identify genes, pathways and processes that are consistently affected across tumors, we mined the literature for gene expression profiles in CTCs. Through *in silico* analysis and the integration of CTC-specific genes, we found highly significant biological mechanisms and regulatory processes acting in CTCs across various cancers, with a particular enrichment of the leukocyte extravasation pathway. This pathway appears to play a pivotal role in the migration of CTCs to distant metastatic sites. We find that CTCs from multiple cancers express both epithelial and mesenchymal markers in varying amounts, which is suggestive of dynamic and hybrid states along the epithelial-mesenchymal transition (EMT) spectrum. Targeting the specific molecular nodes to monitor disease and therapeutic control of CTCs in real time will likely improve the clinical management of cancer progression and metastases.

Nearly 90% of all cancer deaths are attributed to distant tumor metastasis<sup>1</sup>. Metastasis is a multi-step process involving cancer cell invasion into the stroma, intravasation into lymph and blood vessels, survival within the circulation, extravasation, and finally, colonization and proliferation at a secondary organ site<sup>2</sup>. Circulating tumor cells (CTCs), originating from primary or secondary tumors, are a key component of the metastatic cascade and are considered an important indicator of prognosis and cancer relapse. Recent findings suggest that CTCs can serve as non-invasive 'liquid biopsies', allowing clinicians to interrogate the tumor burden and early metastatic events, evaluate treatment response, predict patient sensitivity or resistance to therapies<sup>3</sup>, and provide a way to assess tumor heterogeneity; these collective benefits also point to a more personalized treatment strategy in early stages of the disease<sup>4,5</sup>. Understanding the role of CTCs in disease progression, however, is challenging, as CTCs are believed to exhibit a wide range of epithelial-mesenchymal transition (EMT) phenotypes<sup>6,7</sup>; albeit, there is only limited information available with respect to the role of EMT in CTCs<sup>8</sup> and much of the work addressing EMT regulation has been carried out on cultured cells<sup>7</sup>.

It has been suggested that cancer cell extravasation may have been co-opted from leukocyte extravasation<sup>9</sup>, a well-documented phenomenon involving dynamic interactions between circulating leukocytes and endothelial cells lining the vasculature<sup>10</sup>; although, with some differences. Unlike leukocytes, which express the  $\beta$ 2-integrins that bind directly to intercellular adhesion molecule 1 (ICAM1) receptors, cancer cells do not express  $\beta$ 2-integrins but use leukocytes or other blood cells as bridge- or linker-cells<sup>9</sup>. Specifically, cancer cells are thought to colonize

<sup>1</sup>Institute of Bioinformatics, International Technology Park, Whitefield, Bangalore, 560 066, India. <sup>2</sup>Manipal University, Madhav Nagar, Manipal, 576104, India. <sup>3</sup>Center for Bioinformatics, Pondicherry University, Puducherry 605 014, India. <sup>4</sup>Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine NUS Yong Loo Lin School of Medicine, Singapore 117599, Singapore. <sup>5</sup>Department of Molecular Reproduction, Development and Genetics, Indian Institute of Science, Bangalore, 560012, India. <sup>6</sup>YU-IOB Center for Systems Biology and Molecular Medicine, Yenepoya University, Mangalore, 575018, India. <sup>7</sup>Comprehensive Cancer Center, Institut Gustave Roussy, 114 Rue Edouard Vaillant, 94805 Villejuif, France. <sup>8</sup>CNRS UMR 7057, Matter and Complex Systems, Université Paris Diderot, 10 rue Alice Domon et Léonie Duquet 75013 Paris, France. <sup>9</sup>Department of Biochemistry, National University of Singapore, Singapore 117597, Singapore. Correspondence and requests for materials should be addressed to K.P. (email: prashant@ibioinformatics.org)



**Figure 1.** Schematic of the workflow employed for filtering and integration of data to identify molecular signatures in circulating tumor cells.

inflammatory pre-metastatic niches in secondary organs<sup>11</sup>. Extravasation at these sites may be controlled by E-selectins; cell adhesion molecules expressed on endothelial cells<sup>12</sup>. Further, cancer cell extravasation and possible heterotypic intercellular communication between cancer cells and endothelial cells may be influenced by interactions with molecules such as N-cadherin or galectin-3 on endothelial cells<sup>9</sup>.

Carcinoma cell invasion and migration during metastasis is also influenced by the transition of epithelial cells into motile mesenchymal cells, a process known as epithelial-mesenchymal transition (EMT)<sup>13</sup>. EMT is driven by conserved molecular and cellular developmental programs, which, too, appear to have been hijacked by carcinoma cells to initiate the metastatic cascade<sup>14</sup>. Primary tumors display considerable phenotypic heterogeneity, with carcinoma cells engaged in various stages of EMT. Recent work has confirmed the presence of CTCs with an intermediate or “hybrid” EMT status, and these are believed to confer cells their metastatic potential<sup>15–17</sup>. In our efforts to understand these intermediate states, we previously established an EMT scoring system to estimate EMT dynamics, which ranks the degree of EMT<sup>18</sup>. Yet, this scoring method is still unable to describe the intratumoral heterogeneity of individual cancer cells, including those destined to disseminate, such as CTCs. Experimental data and advanced bioinformatics analyses may help to uncover the role of EMT in systemic transport and extravasation. Few pathway-based approaches have characterized the differential expression of genes that promote metastasis in CTCs<sup>19–22</sup>. Knowledge of the gene expression signatures in CTCs and reconstruction of the inherent CTC signaling network could offer a valuable resource for further functional exploitation, such as in the design of targeted therapies, and in the identification of potential markers to monitor tumor progression and the initial lodging of CTCs in distant organs. This information may ultimately offer a new perspective to target CTCs to prevent tumor cell dissemination and metastasis<sup>23</sup>.

In the present study, we collected, reanalyzed and mapped the gene expression data from several published studies in CTCs to the signaling pathways and networks available to date in an attempt to reveal new insights into CTC signaling. We integrated the transcriptomic changes observed in CTCs across various cancer types to identify with high confidence putative candidate markers involved in extravasation of CTCs. The EMT spectrum was scored for the first time in CTCs from transcriptome datasets to reveal their EMT profile across cancers. The study unfolds some key biological processes that are inherent to these circulating cells.

## Results and Discussion

CTC phenotyping and genotyping studies have expanded our knowledge on tumor progression and tumor evolution<sup>24,25</sup>. Though challenging, the emerging clinical applications of CTCs in cancer detection and disease management are indisputable<sup>26</sup>. We sought to explore unresolved biological and functional facets of CTCs and understand their molecular underpinnings in a clinical context. To this end, we collated and integrated data from gene expression profiles of CTCs within the existing literature, as depicted in the workflow in Fig. 1. Our literature survey using a relevant keyword search in PubMed resulted in 3,242 publications (Supplementary Fig. 1a,b). This was further screened and filtered to a total of 98 papers that were annotated for gene expression data in CTCs

Cancer type	PubMed ID	Experiment type	Differential gene expression in CTCs compared to	Number of differentially expressed genes
Prostate	26383955	RNA sequencing	Primary tumors	4,203
Melanoma	22820318	RNA sequencing	Tumor cell lines	1,138
			Normal melanocytes	685
Breast	25432738	cDNA microarray	Normal epithelium	229
			PBMCs*	434
			Primary tumors	243
Colorectal	22811761	cDNA microarray	PBMCs*	736
Pancreatic	23157946	cDNA microarray	Normal tissue	1,571
			PBMCs*	666
			Primary tumors	1,490


**Table 1. Details of CTC data from high-throughput transcriptomics studies of five cancers.** \*PBMCs – peripheral blood mononuclear cells.

[see Methods]. Differentially expressed genes (DEGs), taken from qualitative and semi-quantitative experiments, resulted in a gene list of 7,572 molecules (denoted as ‘CTC\_ALL’; Supplementary Table S1). Out of these, a list of 7,209 differentially expressed genes from large-scale transcriptomics studies from five cancers were compiled separately (denoted as ‘CTC\_FC’; Supplementary Table S2; Supplementary Fig. 1c). Fold change (FC) values for gene expression in CTCs were available only for the CTC\_FC list<sup>19,20,27–29</sup> (Table 1). Despite major advances in CTC isolation techniques, obtaining pure CTCs from peripheral blood is still challenging. We leveraged expression data from large-scale transcriptomics studies that reported DEGs in CTCs and compiled our gene list for molecular characterization of CTCs predominantly from five such studies based on the quality of their isolation techniques. These five studies have used one or more advanced techniques to overcome the problem of contamination of CTC isolates with hematological and non-viable cells, almost successfully. The details of isolation techniques used to obtain relatively pure CTC populations for these five studies have been compiled in Supplementary Table S3. Improved isolation methods to yield pure populations of CTCs will unfold new opportunities for global gene expression analysis and molecular characterization.

Ingenuity Pathway Analysis (IPA) of the overexpressed genes ( $n = 3,251$ ) in the CTC\_ALL dataset showed significant enrichment of the ‘Leukocyte Extravasation Pathway’ at 44.9% (92/205 molecules associated with ‘Leukocyte Extravasation Signaling’ in IPA;  $p = 6.81E-22$ ;  $z$ -score = 7.180). The top canonical pathways with a positive  $z$ -score included ‘Integrin Signaling’ ( $p = 4.69E-20$ ;  $z$ -score = 8.041), ‘ILK Signaling’ ( $p = 3E-19$ ;  $z$ -score = 6.268), ‘Colorectal Cancer Metastasis Signaling’ ( $p = 8.96E-19$ ;  $z$ -score = 7.507), ‘Glioma Invasiveness Signaling’ ( $p = 1.56E-12$ ;  $z$ -score = 4.7), ‘G $\alpha$ 12/13 Signaling’ ( $p = 1.44E-13$ ;  $z$ -score = 5.259) and ‘B Cell Receptor Signaling’ ( $p = 2E-13$ ;  $z$ -score = 6.862) pathways. These pathways are involved in cell migration, adhesion, growth and differentiation, inhibiting apoptosis and enabling cell survival<sup>30–36</sup>. The top predicted upstream regulator was *TGF $\beta$ 1* ( $p = 2.99E-39$ ), and the IPA gene view indicated *TGF $\beta$ 1* as the upstream regulator of many genes that play a vital role in cancer progression, such as *SERPINE1*, *ACTA2*, *CDKN1A*, *SMAD3*, *SMAD2*, *CTGF*, *FNI*, *CDH1*, *SMAD7*, *COL1A1*, *FOXP3*, *CDKN2B*, *COL1A2*, *VIM*. The top diseases were ‘Cancer’ (total no. of associated molecules = 2,871) and ‘Organismal Injury and Abnormalities’ (2,886), both with a  $p$ -value range of 2.53E-08 to 5.08E-33. The top molecular functions were ‘Cell Death and Survival’ (908;  $p$ -value range, 1.39E-08 to 1.42E-61) with a predicted decrease in cell death and predicted increase in cell survival, and ‘Cellular Growth and Proliferation’ (941;  $p$ -value range, 1.3E-08 to 7.19E-55). Similarly, IPA analysis of the CTC\_FC dataset of overexpressed genes ( $n = 2,652$ ) positioned the leukocyte extravasation pathway as third in the rank of enrichment ( $p = 2.6E-12$ ;  $z$ -score: 6.260). The top ten enriched canonical pathways associated with each dataset are illustrated in Fig. 2.

**CTCs express leukocyte extravasation drivers.** Although comparatively less is known about cancer cell extravasation as compared with that of leukocytes, previous studies suggest a similar process might be operating in CTCs<sup>9,37,38</sup>. Indeed, there is now ample evidence that CTCs may use similar localization/homing signals to that of leukocytes, such as chemokine receptors [stromal cell-derived factor (SDF1/*CXCL12*) and C-X-C motif chemokine receptor 4 (*CXCR4*)] and cytokines [suppressor of cytokine signaling 1 (*SOCS1*)], to guide them to distant metastatic sites to establish new tumors. Furthermore, the expression of these markers has been correlated with the presence of CTCs in peripheral blood and metastasis<sup>39–41</sup>.

The leukocyte extravasation pathway (LEP) is a reasonably well characterized, multi-step process of leukocyte emigration from the blood into tissues through the vascular endothelium and is vital for immune surveillance and inflammation<sup>42</sup>. To explore this further, we expanded the annotated leukocyte extravasation pathway map and built a complete map of the leukocyte/CTC extravasation pathway by integrating information from current pathway resources, review articles and other literature on CTCs (Supplementary Table S4). The entities in our dataset were then mapped to the expanded pathway using the GeneSpring Pathway Architect software tool (version 13.0). The enriched map of the Leukocyte/CTC extravasation pathway generated is shown in Fig. 3. The pathway map illustrates all the upregulated molecules in our datasets (shown in blue colored boxes) that have been identified in CTCs across different cancers that may use a common mode of extravasation and metastatic colonization. The mechanistic roles of the different molecules identified and enriched in the integrated leukocyte/CTC pathway are highlighted and discussed below in greater detail.




**Figure 2. Ingenuity Pathway Analysis (IPA) to identify significant canonical pathways in CTCs.** Top ten canonical pathways associated with genes from (a) CTC\_ALL dataset and (b) CTC\_FC dataset, as shown by IPA pathway analysis. Pathways identified are represented on the y-axis. The x-axis corresponds to the  $-\log$  of the P-value (Fisher's exact test) and the orange points on each pathway bar represent the ratio of the number of genes in a given pathway that meet the cutoff criteria, divided by the total number of genes that map to that pathway.

Extravasation occurs via three sequential steps: (1) rolling, docking and adhesion via endothelial cell adhesion molecules (CAMs); (2) transmigration (extravasation) of leukocytes/CTCs; and (3) the subsequent extravasation of cells across vascular tight junctions<sup>42</sup>. A cancer cell moves along the endothelial lining by leading-edge protrusion and retraction of its tail. Selectins are known to mediate 'rolling' and tethering of leukocytes/tumor cells on the endothelium<sup>12</sup>. After 'docking', signaling is then driven by integrin-mediated interactions<sup>12</sup>. The resulting interactions between several selectins and integrin alpha/beta receptors on the surface of leukocytes/CTCs with the corresponding CAMs on the endothelial cells trigger a cascade of downstream signaling events in both cells<sup>9,12</sup>. In our combined pan-cancer datasets, we found upregulation of several integrins, including *ITGB1*, *ITGB2*, *ITGAL*, *ITGAM* and *ITGA4* and cell adhesion markers such as *ICAM3*, *PECAM1*, *JAM3* and *F11R*. The signal then travels via a chain of phosphorylation events that ultimately lead to phosphorylation and activation of the myosin light chain (MLC), and this causes retraction of the actin cytoskeleton in the tail-end of the migrating leukocyte or CTC<sup>42</sup>. We found several MLC molecules to be upregulated in our datasets (Fig. 3).

Cancer cells and leukocytes both use a group of adhesion receptors called galectins. Galectin-3 (*LGALS3*), known to be overexpressed in circulation of cancer patients, interacts with MUC1 resulting in exposure of cell surface adhesion molecule such as CD44 enhancing cancer cell adhesion<sup>43</sup>. Correspondingly, signaling events within the endothelial cell stimulate endothelial cell retraction followed by localized disassembly of the endothelial adherens junctions comprising cadherins and CAMs by the action of matrix metalloproteases (MMPs), actin remodeling and focal adhesion kinase (FAK) activation. This is consistent with the upregulation of several MMPs observed in our datasets and illustrated in Fig. 3. On the endothelial cell, *ICAM1* signals activate calcium flux and protein kinase C (PKC), which are required for leukocyte migration. Similarly, vascular cell adhesion molecule (*VCAM1*) ligation is required to open the "endothelial passage" by activating the production of reactive oxygen species (ROS) by NADPH oxidase. This in turn activates MMPs, which causes a loss of VE-cadherin-mediated






**Figure 3. Enriched map of the leukocyte extravasation pathway in CTCs.** The pathway diagram illustrates CTC/Leukocyte extravasation through the vascular endothelial lining. The upregulated molecules enriched among CTC\_ALL dataset are highlighted (blue). The leukocyte extravasation pathway was built using the KEGG<sup>96,97</sup> pathway (hsa04670) as a template and further appended with reactions represented in IPA (IPA, Qiagen, Redwood City, <http://www.ingenuity.com/>) pathway resource and extravasation-associated molecular interactions reported in the literature for CTCs. The interactions and their relevant references (PubMed IDs) are tabulated in Supplementary Table S4.

adhesion and allows leukocytes or CTCs to extravasate<sup>42</sup>. Here, we find an upregulation of several components of this multi-subunit NADPH oxidase complex (Fig. 3).

Additionally, recent evidence suggests that platelets contribute to the survival and dissemination of cancer cells by interacting and aggregating around them, which allows cancer cells to evade immune assaults from natural killer cells<sup>44,45</sup>. Platelets release adenosine triphosphate (ATP), which in turn activates endogenous purinergic receptors (*P2Y2*) on cancer cells to mediate their transendothelial migration<sup>46</sup>. Tumor-secreted C-terminal fibrinogen-like domain of angiotensin-like 4 (*ANGPTL4*) instigates vascular ‘leakiness’ and endothelial disruption by binding to integrins and  $\text{TGF}\beta$  via the SMAD signaling pathway<sup>47,48</sup>. In our datasets, we found elevated expression of *ANGPTL2* and *ANGPTL4*. In sum, the enrichment observed in our analyses of the pan-cancer datasets will advance our current understanding of the biological mechanisms behind cancer cell dissemination and allow for a more targeted validation, with the hope to improve the management and prevention of metastatic progression.

Often pathways do not depict all the interconnections and cross-talk, hence in addition to pathways, we constructed a LEP-related network using available protein-protein interactions in STRING database (version 10.0; <http://string-db.org/>) to identify functional hubs with the most number of interactions [data not shown]. Some of the highly connected proteins included SRC, CDC42, PTK2, PXN, PIK3CA, MAPK14, VAV1, ACTB and ITGB2 among others. Earlier network studies on adhesome and EMT showed similar hubs of activity that can be used for targeted studies<sup>49,50</sup>. SRC, having the most connections in LEP network has been implicated in motility-regulating anoikis and microtentacle formation<sup>51,52</sup>, and disruption of SRC was found to suppress tumor cell extravasation<sup>53</sup>. These hubs may serve as prominent targets that can be investigated further in CTCs for therapeutic purposes.

While our observations center on gene expression changes in CTCs, we also found expression changes in several genes previously reported in endothelial cells (Fig. 3). We do realize that although care was taken in these studies to obtain a pure population of CTCs as mentioned previously, given the challenges involved in CTC isolation, some contamination with leukocytes and/or endothelial cells may occur, thus contributing to the observed changes in expression levels. However, other possibilities may exist wherein cancer cells can take on the functions of endothelial cells. Recently, a phenomenon called vascular mimicry (VM) has gained significance in tumor malignancies, including invasion and metastasis. VM in cancer cells leads to *de novo* vasculogenesis, wherein cancer cells express endothelial cell markers and an endothelial cell phenotype<sup>54,55</sup>, and permit the transfer of oxygen and nutrients<sup>56</sup> in the tumor bed without coagulation events. Cancer cells endowed with VM harbor stem cell-like properties of chemoresistance and can develop into different cell types<sup>57,58</sup>. PIK2/Akt signaling pathway is activated in VM, which in turn activates MMPs. These proteases cleave Ln-5Y<sup>2</sup> chains, and the resulting fragments create plasticity within the extracellular matrix (ECM)<sup>59</sup>. FAK, which we observed to be overexpressed in the pancreatic and melanoma CTC datasets, activates ERK1/2, which induces VM via MMPs<sup>60,61</sup>. We also observed overexpression of *HIF1A*—a master regulator of responses to hypoxia—in the prostate CTCs dataset. *HIF1A* activates VEGF expression, which in turn promotes VM by inducing EMT<sup>62,63</sup>. Further in-depth investigations and molecular characterizations of VM in tumor cells may reveal novel insights into the metastatic process.




**Figure 4.** Unsupervised hierarchical clustering for differentially expressed genes in CTCs. (a) Heat map depicting hierarchical unsupervised clustering of gene expression profiles across the CTC subgroups from five cancers. Zoomed section of heat map shows the top 50 abundant genes across cancers; genes of interest are color-coded. Red in the heat map represents highly expressed genes, whereas green represents downregulated genes. (b) Principal component analysis showing the variance in gene expression datasets among CTC subgroups of five cancers.

**Unsupervised clustering of differentially expressed genes in CTCs.** To understand the gene expression profiles observed in CTCs among various cancers and identify signatures, we performed unsupervised clustering (using GENE-E version 3.0.206; <http://www.broadinstitute.org/cancer/software/GENE-E/index.html>) and principal component analysis (using GeneSpring GX software version 13.0) on differentially expressed gene datasets from the CTC\_FC list (Fig. 4a,b, respectively). The top gene transcript, secreted protein acid and rich in cysteine (*SPARC*), codes for an important ECM protein reported to be differentially expressed and a modulator of several cellular processes required for metastasis initiation in the tumor microenvironment<sup>64,65</sup>. In colorectal, ovarian and prostate cancers, *SPARC* acts as a tumor suppressor by repressing angiogenesis by inhibiting vascular endothelial growth factor (VEGF); whereas, in pancreatic, breast, melanoma and glioblastoma cancers, its overexpression leads to the activation of MMPs, which in turn promote EMT<sup>66</sup>. *SPARC* has been shown to be necessary in pancreatic cancer metastasis<sup>67</sup>, and stromal *SPARC* overexpression is associated with poor survival<sup>68,69</sup>. It has therefore gained interest as a potential prognostic and therapeutic target in pancreatic cancer. We also observed downregulation of Histidine triad NucleoTide-binding protein 1 (*HINT1*) in colorectal, pancreatic and breast CTCs (Fig. 4a). *HINT1* was recently considered a tumor suppressor gene<sup>70</sup>; although, its role in cancer metastasis is unclear<sup>71</sup>. We also found downregulation in genes involved in apoptosis in pancreatic (*BCLAF1*, *FAM162A*), breast (*BCLAF1*) and melanoma (*FAM162A*) CTCs.

Platelet activation and aggregation with CTCs not only protects cancer cells from natural killer cells and immune surveillance but can also prime them for metastasis<sup>72,73</sup>. Platelets play a major role in scaffolding the cancer cells and aid in their survival in circulation<sup>74</sup>. We found elevated expression of genes involved in platelet activation, such as *ABCC4*, *ACTN1*, *APP*, *ESAM*, *F13A1* and *GNG11*, in colorectal and pancreatic CTCs. Platelets secrete TGF $\beta$ 1, which activates the TGF $\beta$ /Smad pathway in cancer cells and, at the same time, the platelet–cancer cell interaction activates the NF- $\kappa$ B pathway in cancer cells. These events trigger synergism between the pathways to promote metastasis<sup>72</sup>. They also assist in extravasation by releasing ATP molecules that activate the *P2Y2* receptors on cancer cells to permit transendothelial migration<sup>46</sup>.

Plastin 3 (*PLS3*) [data not shown in Fig. 4a but listed in Supplementary Table S1], a prominent CTC marker, was also differentially expressed in our screen. *PLS3* is strongly associated with prognosis of metastatic cancers; yet, others show that *PLS3* expression is unaffected during the EMT process<sup>75,76</sup>. Accordingly, we noted an overexpression of *PLS3* mRNA in breast and colorectal CTCs datasets but downregulation in prostate CTCs.

Patterns of differentially expressed genes in CTCs when compared to primary tumors or peripheral blood mononuclear cells (PBMCs) or normal tissue (Supplementary Fig. 2) were visualized by unsupervised clustering of DEGs for each sub-group (Fig. 5). We observed that colorectal CTCs and pancreatic CTCs showed similar gene expression profiles at the transcriptomic level and in their primary tumors. This could mean that CTC expression profiles could be used to reveal distinct expression patterns in some cancer types; understanding the diversities




**Figure 5. Unsupervised data-driven stratification of CTCs in relation to specific subgroups.** (a) Heat map representing hierarchical unsupervised clustering of differentially expressed genes in CTCs when compared with primary tumors. (b) Unsupervised clustering of differentially expressed genes in CTCs when compared with peripheral blood mononuclear cells (PBMcs). (c) Unsupervised clustering of differentially expressed genes in CTCs when compared with normal tissue.

or similarities in CTC profiles across various cancer types may offer insights for the design of new therapeutic strategies<sup>77,78</sup>.


**Epithelial-Mesenchymal transition profile in CTCs.** EMT is a key event involved in promoting the dissemination of carcinoma cells to distant organs<sup>13</sup>. We recently established a quantitative EMT scoring system across more than 15 cancers based on gene expression profiles<sup>18</sup>. This generic EMT signature for tumors and cell lines of different origins reflect not only the epithelial and mesenchymal states but also potential intermediate states that occur during the transition. Several studies have shown that CTCs exhibit a broad spectrum of EMT phenotypes, independent of carcinoma cell characteristics in primary tumors<sup>17,79</sup>. Epithelial markers (for example, EPCAM) are generally used to isolate CTCs from blood. However, CTCs exhibiting the full spectrum of EMT phenotypes will not be captured by this method, and CTCs thus isolated will not represent the entire population of CTCs in the blood.

In a benchmark study, circulating breast cancer cells were shown to express both epithelial and mesenchymal markers<sup>17</sup>. This observation was supported in a subsequent study by our group<sup>80</sup>, where we employed RNA-FISH to identify transcripts encoding various EMT markers (epithelial: E-cadherin, CK5, CK7, CK18, CK19, and EPCAM; and mesenchymal: *VIM* and *FSCN1*). We found heterogeneous expression of both epithelial and mesenchymal markers in the cultured CTCs. In concordance, others also suggest that CTCs from various cancer types may exhibit a dynamic EMT profile, and possibly showing an intermediate phenotype rather than a complete epithelial or mesenchymal state<sup>6</sup>.

The plasticity between epithelial and mesenchymal states in CTCs across cancers was assessed in two ways; 1) we employed the EMT scoring method<sup>18</sup> [see Methods] to compute the generic EMT scores using transcriptome datasets from the five cancer studies (same studies used to generate CTC\_FC dataset; Table 1). Figure 6 shows the distribution of the EMT scores in CTCs in each cancer type. Scores closer to +1.0 suggest a more mesenchymal-like (Mes) phenotype, and scores nearer to -1.0 reflect epithelial-like (Epi) phenotype. The EMT scores in our CTC datasets were distributed between -0.3 to +0.5, suggestive of intermediate phenotypes. The plot further shows a slightly higher expression of mesenchymal genes in melanoma and pancreatic cancer (Mean EMT scores - melanoma, +0.4; pancreatic, +0.2), which are suggestive of intermediate mesenchymal phenotypes and may reflect their ability to metastasize at an early stage<sup>81-83</sup>. In accordance with our previously reported intermediate EMT scores in a mixed population of breast cancer cell lines of Basal and Luminal phenotypes<sup>18</sup>, the breast CTCs in our dataset (subtyped as Basal and Luminal B<sup>29</sup>) also show intermediate mesenchymal scores; 2) we mapped the gene expression data from 'CTC\_FC' dataset to the EMT signature genes (total = 418; epithelial = 228 and mesenchymal = 188) derived using gene expression profiles from tumor and cell lines from various cancers<sup>18,84,85</sup>. The distribution of expression values observed for the EMT signature genes in the CTC\_FC dataset is shown in Supplementary Fig. 3. The swarm plot shows co-expression of epithelial and mesenchymal markers in CTCs derived from the five cancers. The observation from both analyses is in concordance with earlier



**Figure 6. Epithelial-mesenchymal transition (EMT) scores across various cancers.** Box plot-Dot plot gives the degree of EMT scores in a collection of CTCs from five cancers. EMT scores closer to +1.0 or -1.0 reflect more mesenchymal (Mes) or epithelial (Epi) states, respectively with potential intermediate states in between. Color code: red, pancreatic CTCs; maroon, colorectal CTCs; green, breast CTCs; blue, melanoma CTCs; purple, prostate CTCs.



**Figure 7. Integrated regulatory network for EMT in CTCs.** Regulatory network depicting molecular interactions of EMT genes in CTCs across three cancers. The epithelial markers reported in our dataset are represented in green ovals; mesenchymal markers in red ovals. The yellow ovals represent other key EMT molecules reported in literature but not identified in our dataset.

studies based on experimental<sup>86</sup> and mathematical models<sup>87</sup>, indicating an intermediate EMT phenotype in CTCs across cancers. The hybrid intermediate state may act as a crucial driver for tumor progression and metastatic colonization.

In addition, we computed the EMT scores for each cancer CTC dataset and compared them with their respective tumor and cancer cell lines EMT scores [see Methods]. The EMT score spectrum of CTCs exhibit similarities with our published<sup>18</sup> cancer-specific EMT landscape of respective cell lines and tumors, albeit the average EMT score of CTCs is slightly higher in the case of colon, breast and pancreatic cancer datasets. As the EMT spectrum of CTCs resemble their tumor and cancer cell line counterparts more closely, this observation may add further evidence to substantiate that the gene expression data for the five cancer studies have been derived from a relatively pure population of CTC and not from cells of hematological origin. Future CTC expression studies with improved isolation techniques and comparison with expression profiles of different cell types will help to comprehensively characterize the molecular signatures of CTCs.

Considering the disparate nature of the CTC\_FC dataset, we built a gene interaction-based functional EMT network using a selected subset of gene expression data from colorectal, pancreatic and breast CTCs (DEGs when compared to PBMCs); this was done to acquire an accurate comparison of differential values and allow us to segregate high-confident EMT hub molecules from the network. The EMT network (Fig. 7) was built using Cytoscape<sup>88</sup> (version 3.3.0; <http://www.cytoscape.org/>) by including key EMT regulators. The differential gene expression data from CTCs were then overlaid on this network. We noted an upregulation in *SPARC*, *MYLK*, *MYL6*, *GG11*, *F13A1* and *FHL1* (mesenchymal markers) and *CD9*, *LCN2*, and *ABCC3* (epithelial markers) in



CTCs of at least two cancers. *SPARC* (also observed as top molecule in unsupervised clustering) is a well-known marker associated with invasion and an important mediator of bone metastasis<sup>89,90</sup>. Interestingly, *MYLK* and *CD9* have been implicated in lymph node metastasis in different cancers<sup>91,92</sup>, whereas *ABCC3* overexpression is reportedly involved in glycolysis, drug resistance and overall poor prognosis in bladder cancer [not in our dataset]<sup>89,93</sup>. However, some markers may play a tumor-specific role, as the loss of *FHL1* has been linked with increased metastasis in esophageal and gastric cancers<sup>93,94</sup> [these cancers are not represented in our dataset]. Increased secretion of lipocalin-2 (*LCN2*), a tissue-specific factor not found in peripheral blood leukocytes, was reported in a CTC-derived cell line (BHGc7) from relapsed lung cancer patients<sup>95</sup>. Thus, CTC EMT phenotypes in different cancers may provide important, high-confidence leads to monitor tumor-specific or CTC-specific events following therapeutic intervention.

## Concluding Remarks

This study has uncovered promising CTC-driven signaling nodes in the extravasation pathway and identified the key contributors that may determine favorable clinical outcomes. These CTC-associated signaling profiles will provide a valuable resource to identify downstream events crucial to the functioning of CTCs in the metastatic cascade. These findings bring us further toward understanding the mechanisms of various biological processing pathways within the circulating cell and pave the way for the identification of appropriate therapeutic targets against CTC, metastasis and cancer.

## Methods

We employed a multi-stage screening and filtering strategy to identify molecular signatures in CTCs. Briefly, we screened the literature for articles published on CTC expression. A list of all differentially expressed genes was prepared and used to identify significantly altered pathways and networks.

**Literature survey.** PubMed was searched using keywords ‘circulating tumor cells signaling’ (November 9, 2015) which resulted in 1,073 publications. These publications were reviewed at the abstract level and 153 papers were narrowed down for further screening. Another PubMed search was carried out using keywords ‘circulating tumor cells gene expression’ (February 5, 2016), which resulted in 2,169 publications. Further review narrowed this down to 78 publications. Of the 231 (153 + 78) papers, 98 (42.4%) were thoroughly annotated for gene expression in CTCs [see Additional Supplementary Information and Supplementary Table S5]. Gene expression data were taken from semi-quantitative and qualitative experiments for gene annotation. This lenient but statistically significant ( $p < 0.05$ ) gene list constituted genes reported to be overexpressed or downregulated in CTCs when compared to primary tumors, cancer cell lines, peripheral blood mononuclear cells (PBMCs), or normal tissue (each classified as CTC sub-group in the manuscript). Gene expression data were taken from studies that evaluated cancer patient CTC levels, cancer cells cultured *ex vivo* and spiked into the blood collected from healthy individuals, or CTCs isolated from blood of orthotopically grafted tumors in mice. From this extensive dataset compiled from 98 papers, data of differentially expressed genes from five large-scale transcriptomics studies across five different cancers was collated separately to generate a unique gene list with fold change values. Two of the five studies used RNA sequencing experiments and three used cDNA microarray to capture expression data. Details of the source for datasets are provided in Table 1.

**Transcriptomics dataset analysis.** Transcriptome datasets were compiled from both high-throughput RNA-Seq experiments and microarray experiments (whichever available) related to CTCs. Supplementary results were compiled where available; otherwise data were processed to obtain the final set of genes. From the semi-quantitative experiments, sets of statistically significant, differentially expressed genes (DEG) with a log<sub>2</sub> fold change cutoff of 1.5 and  $p$ -value  $< 0.05$  were considered for downstream analysis. The colorectal and pancreatic microarray gene expression data (Gene Expression Omnibus repository; Accession Number: GSE31023 and GSE18670, respectively. <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE31023> and <https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE18670>) were reanalyzed using GEO2R (<http://www.ncbi.nlm.nih.gov/geo/geo2r/>) package to obtain the set of DEGs in CTCs. RNA-Seq data from the prostate cancer study were also reanalyzed to obtain genes that were differentially expressed with log<sub>2</sub> fold change of 1.5 or higher using an in-house bioinformatics pipeline. Genes were filtered to include only the protein-coding genes for pathway analysis. Any pseudogenes, uncharacterized genes, non-coding RNA gene annotation were excluded. Entrez Gene IDs and gene biotype information were retrieved using the Ensemble Biomart (<http://asia.ensembl.org/biomart/martview/>) tool for human genome assembly; GRCh38p.5. Genes from various datasets were aggregated to form a master list of non-redundant DEGs.

For EMT scoring, transcriptome datasets of CTC from the five cancer studies (Table 1; Supplementary Table S6)—GSE18670, GSE31023, GSE38495, GSE45965, and GSE67980 were downloaded from GEO. The pre-processed data GSE45965 was also used. Dataset on Affymetrix platform (GSE18670) was RMA normalized using R version 3.3.1, Affy 1.50.0, whereas dataset on Agilent platform (GSE31023) was normalized using R limma 3.28.21. The RPM and RPKM normalized were extracted for RNA-Seq data GSE38495 and GSE67980. EMT score was computed using signatures and methods detailed in our previous study<sup>18</sup>.

Further, we computed the EMT scores for each of the five cancer CTC datasets using the gene expression data from genes overlapping across the datasets ( $n = 3167$ ) and compared them to previously computed EMT scores for each tumor type and its cancer cell line collection<sup>18</sup> (Supplementary Fig. 4)

**Pathway analysis.** Two sets of data were used for pathway analysis: (1) the lenient gene list collated from 98 studies and (2) the differentially expressed genes list from the five high-throughput transcriptomics studies. (Denoted as CTC\_ALL and CTC\_FC (FC = fold-change), respectively for the purpose of differentiating between the datasets.)

The Ingenuity pathway analysis (IPA–Build: 377306 M; Version: 27216297; IPA, Qiagen, Redwood City, <http://www.ingenuity.com/>) tool was used for pathway analysis. Relationships of molecules differentially expressed in our dataset were inspected using the Core Analysis module in IPA Ingenuity Knowledge Base reference repository. Only the overexpressed genes from the CTC\_ALL and CTC\_FC datasets were uploaded into IPA, separately. Canonical pathway analyses identified the top canonical pathways that were significant in our datasets.

PathVisio (3.2.1; revision 4025; [www.pathvisio.org](http://www.pathvisio.org)), a free, open-source software for drawing and editing biological pathways, was used to manually depict the enrichment for Leukocyte Extravasation Signaling. Molecular interaction data were sourced from the KEGG pathway database (<http://www.genome.jp/kegg/>) and IPA pathways (IPA, Qiagen, Redwood City, <http://www.ingenuity.com/>). Literature mining was done for reported signaling patterns in CTCs, and only a handful of publications were available. Molecular interactions were annotated from these publications and appended onto the depicted pathway. An internal pathway review system was followed to carefully inspect for erroneous annotations. The pathway map was uploaded to GeneSpring software provided by Agilent Technologies (software version 13.0; <http://www.genomics.agilent.com/en/Microarray-Data-Analysis-Software/GeneSpring-GX/?cid=AG-PT-130&tabId=AG-PR-1061>) for enrichment. The gene list used for enrichment was identical to that used for IPA analysis (CTC\_ALL, overexpressed genes n = 3,251).

STRING (version 10.0; <http://string-db.org/>) database was used for generating protein-protein interactions and Cytoscape (version 3.3.0; <http://www.cytoscape.org/>), an open-source platform, was used for visualizing the EMT biological pathways and molecular interaction network, and integrating the CTC gene expression data. In-house python scripts and the Adobe Illustrator (version CS5.1) graphics editor were used to draw or edit the figures.

## References

- Weigelt, B., Peterse, J. L. & van 't Veer, L. J. Breast cancer metastasis: markers and models. *Nature reviews. Cancer* **5**, 591–602, doi: 10.1038/nrc1670 (2005).
- Valastyan, S. & Weinberg, R. A. Tumor metastasis: molecular insights and evolving paradigms. *Cell* **147**, 275–292, doi: 10.1016/j.cell.2011.09.024 (2011).
- Datar, I. & Schalper, K. A. Epithelial-Mesenchymal Transition and Immune Evasion during Lung Cancer Progression: The Chicken or the Egg? *Clinical cancer research: an official journal of the American Association for Cancer Research* **22**, 3422–3424, doi: 10.1158/1078-0432.CCR-16-0336 (2016).
- Pantel, K. & Alix-Panabieres, C. Circulating tumour cells in cancer patients: challenges and perspectives. *Trends in molecular medicine* **16**, 398–406, doi: 10.1016/j.molmed.2010.07.001 (2010).
- Toss, A., Mu, Z., Fernandez, S. & Cristofanilli, M. CTC enumeration and characterization: moving toward personalized medicine. *Annals of translational medicine* **2**, 108, doi: 10.3978/j.issn.2305-5839.2014.09.06 (2014).
- Li, W. & Kang, Y. Probing the Fifty Shades of EMT in Metastasis. *Trends in cancer* **2**, 65–67, doi: 10.1016/j.trecan.2016.01.001 (2016).
- Nieto, M. A., Huang, R. Y., Jackson, R. A. & Thiery, J. P. EMT: 2016. *Cell* **166**, 21–45, doi: 10.1016/j.cell.2016.06.028 (2016).
- Bednarz-Knoll, N., Alix-Panabieres, C. & Pantel, K. Plasticity of disseminating cancer cells in patients with epithelial malignancies. *Cancer metastasis reviews* **31**, 673–687, doi: 10.1007/s10555-012-9370-z (2012).
- Strell, C. & Entschladen, F. Extravasation of leukocytes in comparison to tumor cells. *Cell communication and signaling: CCS* **6**, 10, doi: 10.1186/1478-811X-6-10 (2008).
- Langer, H. F. & Chavakis, T. Leukocyte-endothelial interactions in inflammation. *Journal of cellular and molecular medicine* **13**, 1211–1220, doi: 10.1111/j.1582-4934.2009.00811.x (2009).
- Costa-Silva, B. *et al.* Pancreatic cancer exosomes initiate pre-metastatic niche formation in the liver. *Nature cell biology* **17**, 816–826, doi: 10.1038/ncb3169 (2015).
- Bendas, G. & Borsig, L. Cancer cell adhesion and metastasis: selectins, integrins, and the inhibitory potential of heparins. *Int J Cell Biol* **2012**, 676731, doi: 10.1155/2012/676731 (2012).
- Chaffer, C. L. & Weinberg, R. A. A perspective on cancer cell metastasis. *Science* **331**, 1559–1564, doi: 10.1126/science.1203543 (2011).
- Lim, J. & Thiery, J. P. Epithelial-mesenchymal transitions: insights from development. *Development* **139**, 3471–3486, doi: 10.1242/dev.071209 (2012).
- Mego, M. *et al.* Expression of epithelial-mesenchymal transition-inducing transcription factors in primary breast cancer: The effect of neoadjuvant therapy. *International journal of cancer* **130**, 808–816, doi: 10.1002/ijc.26037 (2012).
- Alix-Panabieres, C. & Pantel, K. Technologies for detection of circulating tumor cells: facts and vision. *Lab on a chip* **14**, 57–62, doi: 10.1039/c3lc50644d (2014).
- Yu, M. *et al.* Circulating breast tumor cells exhibit dynamic changes in epithelial and mesenchymal composition. *Science* **339**, 580–584, doi: 10.1126/science.1228522 (2013).
- Tan, T. Z. *et al.* Epithelial-mesenchymal transition spectrum quantification and its efficacy in deciphering survival and drug responses of cancer patients. *EMBO molecular medicine* **6**, 1279–1293, doi: 10.15252/emmm.201404208 (2014).
- Barbazan, J. *et al.* Molecular characterization of circulating tumor cells in human metastatic colorectal cancer. *PLoS one* **7**, e40476, doi: 10.1371/journal.pone.0040476 (2012).
- Sergeant, G., van Eijnsden, R., Roskams, T., Van Duppen, V. & Topal, B. Pancreatic cancer circulating tumour cells express a cell motility gene signature that predicts survival after surgery. *BMC cancer* **12**, 527, doi: 10.1186/1471-2407-12-527 (2012).
- Molloy, T. J., Roepman, P., Naume, B. & van't Veer, L. J. A prognostic gene expression profile that predicts circulating tumor cell presence in breast cancer patients. *PLoS one* **7**, e32426, doi: 10.1371/journal.pone.0032426 (2012).
- Cann, G. M. *et al.* mRNA-Seq of single prostate cancer circulating tumor cells reveals recapitulation of gene expression and pathways found in prostate cancer. *PLoS one* **7**, e49144, doi: 10.1371/journal.pone.0049144 (2012).
- Faltas, B. Cornering metastases: therapeutic targeting of circulating tumor cells and stem cells. *Front Oncol* **2**, 68, doi: 10.3389/fonc.2012.00068 (2012).
- Fidler, I. J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. *Nature reviews. Cancer* **3**, 453–458, doi: 10.1038/nrc1098 (2003).
- Fehm, T. *et al.* Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. *Clinical cancer research: an official journal of the American Association for Cancer Research* **8**, 2073–2084 (2002).
- Alix-Panabieres, C. & Pantel, K. Clinical Applications of Circulating Tumor Cells and Circulating Tumor DNA as Liquid Biopsy. *Cancer discovery* **6**, 479–491, doi: 10.1158/2159-8290.CD-15-1483 (2016).
- Miyamoto, D. T. *et al.* RNA-Seq of single prostate CTCs implicates noncanonical Wnt signaling in antiandrogen resistance. *Science* **349**, 1351–1356, doi: 10.1126/science.aab0917 (2015).

28. Ramskold, D. *et al.* Full-length mRNA-Seq from single-cell levels of RNA and individual circulating tumor cells. *Nature biotechnology* **30**, 777–782, doi: 10.1038/nbt.2282 (2012).
29. Lang, J. E. *et al.* Expression profiling of circulating tumor cells in metastatic breast cancer. *Breast cancer research and treatment* **149**, 121–131, doi: 10.1007/s10549-014-3215-0 (2015).
30. Desgrosellier, J. S. & Cheresch, D. A. Integrins in cancer: biological implications and therapeutic opportunities. *Nature reviews. Cancer* **10**, 9–22, doi: 10.1038/nrc2748 (2010).
31. Persad, S. & Dedhar, S. The role of integrin-linked kinase (ILK) in cancer progression. *Cancer metastasis reviews* **22**, 375–384 (2003).
32. Hannigan, G., Troussard, A. A. & Dedhar, S. Integrin-linked kinase: a cancer therapeutic target unique among its ILK. *Nature reviews. Cancer* **5**, 51–63, doi: 10.1038/nrc1524 (2005).
33. Colussi, D., Brandi, G., Bazzoli, F. & Ricciardiello, L. Molecular pathways involved in colorectal cancer: implications for disease behavior and prevention. *International journal of molecular sciences* **14**, 16365–16385, doi: 10.3390/ijms140816365 (2013).
34. Ten Hacken, E. & Burger, J. A. Microenvironment interactions and B-cell receptor signaling in Chronic Lymphocytic Leukemia: Implications for disease pathogenesis and treatment. *Biochimica et biophysica acta* **1863**, 401–413, doi: 10.1016/j.bbamcr.2015.07.009 (2016).
35. Paw, I., Carpenter, R. C., Watabe, K., Debinski, W. & Lo, H. W. Mechanisms regulating glioma invasion. *Cancer letters* **362**, 1–7, doi: 10.1016/j.canlet.2015.03.015 (2015).
36. Chia, C. Y., Kumari, U. & Casey, P. J. Breast cancer cell invasion mediated by Galpha12 signaling involves expression of interleukins-6 and -8, and matrix metalloproteinase-2. *Journal of molecular signaling* **9**, 6, doi: 10.1186/1750-2187-9-6 (2014).
37. Miles, F. L., Pruitt, F. L., van Golen, K. L. & Cooper, C. R. Stepping out of the flow: capillary extravasation in cancer metastasis. *Clin Exp Metastasis* **25**, 305–324, doi: 10.1007/s10585-007-9098-2 (2008).
38. Muller, A. *et al.* Involvement of chemokine receptors in breast cancer metastasis. *Nature* **410**, 50–56, doi: 10.1038/35065016 (2001).
39. Smolkova, B. *et al.* Expression of SOCS1 and CXCL12 Proteins in Primary Breast Cancer Are Associated with Presence of Circulating Tumor Cells in Peripheral Blood. *Transl Oncol* **9**, 184–190, doi: 10.1016/j.tranon.2016.03.004 (2016).
40. Balkwill, F. Cancer and the chemokine network. *Nature reviews. Cancer* **4**, 540–550, doi: 10.1038/nrc1388 (2004).
41. Burger, J. A. & Kipps, T. J. CXCR4: a key receptor in the crosstalk between tumor cells and their microenvironment. *Blood* **107**, 1761–1767, doi: 10.1182/blood-2005-08-3182 (2006).
42. Muller, W. A. Mechanisms of leukocyte transendothelial migration. *Annu Rev Pathol* **6**, 323–344, doi: 10.1146/annurev-pathol-011110-130224 (2011).
43. Zhao, Q. *et al.* Circulating galectin-3 promotes metastasis by modifying MUC1 localization on cancer cell surface. *Cancer research* **69**, 6799–6806, doi: 10.1158/0008-5472.CAN-09-1096 (2009).
44. Leblanc, R. & Peyruchaud, O. Metastasis: new functional implications of platelets and megakaryocytes. *Blood* **128**, 24–31, doi: 10.1182/blood-2016-01-636399 (2016).
45. Amo, L. *et al.* Involvement of platelet-tumor cell interaction in immune evasion. Potential role of podocalyxin-like protein 1. *Front Oncol* **4**, 245, doi: 10.3389/fonc.2014.00245 (2014).
46. Schumacher, D., Strilic, B., Sivaraj, K. K., Wetschurck, N. & Offermanns, S. Platelet-derived nucleotides promote tumor-cell transendothelial migration and metastasis via P2Y2 receptor. *Cancer Cell* **24**, 130–137, doi: 10.1016/j.ccr.2013.05.008 (2013).
47. Huang, R. L. *et al.* ANGPTL4 modulates vascular junction integrity by integrin signaling and disruption of intercellular VE-cadherin and claudin-5 clusters. *Blood* **118**, 3990–4002, doi: 10.1182/blood-2011-01-328716 (2011).
48. Padua, D. *et al.* TGFbeta primes breast tumors for lung metastasis seeding through angiopoietin-like 4. *Cell* **133**, 66–77, doi: 10.1016/j.cell.2008.01.046 (2008).
49. Zaidel-Bar, R., Itzkovitz, S., Maayan, A., Iyengar, R. & Geiger, B. Functional atlas of the integrin adhesome. *Nature cell biology* **9**, 858–867, doi: 10.1038/ncb0807-858 (2007).
50. Zhao, M., Kong, L., Liu, Y. & Qu, H. dbEMT: an epithelial-mesenchymal transition associated gene resource. *Scientific reports* **5**, 11459, doi: 10.1038/srep11459 (2015).
51. Windham, T. C. *et al.* Src activation regulates anoikis in human colon tumor cell lines. *Oncogene* **21**, 7797–7807, doi: 10.1038/sj.onc.1205989 (2002).
52. Balzer, E. M. *et al.* c-Src differentially regulates the functions of microtentacles and invadopodia. *Oncogene* **29**, 6402–6408, doi: 10.1038/onc.2010.360 (2010).
53. Weis, S., Cui, J., Barnes, L. & Cheresch, D. Endothelial barrier disruption by VEGF-mediated Src activity potentiates tumor cell extravasation and metastasis. *The Journal of cell biology* **167**, 223–229, doi: 10.1083/jcb.200408130 (2004).
54. Maniotis, A. J. *et al.* Vascular channel formation by human melanoma cells *in vivo* and *in vitro*: vasculogenic mimicry. *The American journal of pathology* **155**, 739–752, doi: 10.1016/S0002-9440(10)65173-5 (1999).
55. Folberg, R., Hendrix, M. J. & Maniotis, A. J. Vasculogenic mimicry and tumor angiogenesis. *The American journal of pathology* **156**, 361–381, doi: 10.1016/S0002-9440(10)64739-6 (2000).
56. Dunleavey, J. M. & Dudley, A. C. Vascular Mimicry: Concepts and Implications for Anti-Angiogenic Therapy. *Current angiogenesis* **1**, 133–138, doi: 10.2174/2211552811201020133 (2012).
57. Larson, A. R. *et al.* Melanoma spheroid formation involves laminin-associated vasculogenic mimicry. *The American journal of pathology* **184**, 71–78, doi: 10.1016/j.ajpath.2013.09.020 (2014).
58. Lezcano, C. *et al.* Merkel cell carcinoma expresses vasculogenic mimicry: demonstration in patients and experimental manipulation in xenografts. *Lab Invest* **94**, 1092–1102, doi: 10.1038/labinvest.2014.99 (2014).
59. Sefror, R. E. *et al.* Cooperative interactions of laminin 5 gamma2 chain, matrix metalloproteinase-2, and membrane type-1-matrix/metalloproteinase are required for mimicry of embryonic vasculogenesis by aggressive melanoma. *Cancer research* **61**, 6322–6327 (2001).
60. Hess, A. R. & Hendrix, M. J. Focal adhesion kinase signaling and the aggressive melanoma phenotype. *Cell Cycle* **5**, 478–480, doi: 10.4161/cc.5.5.2518 (2006).
61. Hess, A. R. *et al.* Focal adhesion kinase promotes the aggressive melanoma phenotype. *Cancer research* **65**, 9851–9860, doi: 10.1158/0008-5472.CAN-05-2172 (2005).
62. Du, J. *et al.* Hypoxia promotes vasculogenic mimicry formation by inducing epithelial-mesenchymal transition in ovarian carcinoma. *Gynecologic oncology* **133**, 575–583, doi: 10.1016/j.ygyno.2014.02.034 (2014).
63. Qiao, L. *et al.* Advanced research on vasculogenic mimicry in cancer. *Journal of cellular and molecular medicine* **19**, 315–326, doi: 10.1111/jcmm.12496 (2015).
64. Brekken, R. A. & Sage, E. H. SPARC, a matricellular protein: at the crossroads of cell-matrix. *Matrix biology: journal of the International Society for Matrix Biology* **19**, 569–580 (2000).
65. Thomas, S. L. & Rempel, S. A. In *Tumor-Associated Fibroblasts and their Matrix: Tumor Stroma* (eds M., Margareta Mueller & E., Norbert Fusenig) 301–346 (Springer Netherlands, 2011).
66. Neuzillet, C. *et al.* Stromal expression of SPARC in pancreatic adenocarcinoma. *Cancer metastasis reviews* **32**, 585–602, doi: 10.1007/s10555-013-9439-3 (2013).
67. Ting, D. T. *et al.* Single-cell RNA sequencing identifies extracellular matrix gene expression by pancreatic circulating tumor cells. *Cell reports* **8**, 1905–1918, doi: 10.1016/j.celrep.2014.08.029 (2014).

68. Gundewar, C., Sasor, A., Hilmersson, K. S., Andersson, R. & Ansari, D. The role of SPARC expression in pancreatic cancer progression and patient survival. *Scandinavian journal of gastroenterology* **50**, 1170–1174, doi: 10.3109/00365521.2015.1024281 (2015).
69. Vaz, J., Ansari, D., Sasor, A. & Andersson, R. SPARC: A Potential Prognostic and Therapeutic Target in Pancreatic Cancer. *Pancreas* **44**, 1024–1035, doi: 10.1097/MPA.0000000000000409 (2015).
70. Li, H., Zhang, Y., Su, T., Santella, R. M. & Weinstein, I. B. Hint1 is a haplo-insufficient tumor suppressor in mice. *Oncogene* **25**, 713–721, doi: 10.1038/sj.onc.1209111 (2006).
71. Martin, J., St-Pierre, M. V. & Dufour, J. F. Hit proteins, mitochondria and cancer. *Biochimica et biophysica acta* **1807**, 626–632, doi: 10.1016/j.bbabbio.2011.02.001 (2011).
72. Labelle, M., Begum, S. & Hynes, R. O. Direct signaling between platelets and cancer cells induces an epithelial-mesenchymal-like transition and promotes metastasis. *Cancer Cell* **20**, 576–590, doi: 10.1016/j.ccr.2011.09.009 (2011).
73. Gay, L. J. & Felding-Habermann, B. Contribution of platelets to tumour metastasis. *Nature reviews. Cancer* **11**, 123–134, doi: 10.1038/nrc3004 (2011).
74. Jain, S., Harris, J. & Ware, J. Platelets: linking hemostasis and cancer. *Arteriosclerosis, thrombosis, and vascular biology* **30**, 2362–2367, doi: 10.1161/ATVBAHA.110.207514 (2010).
75. Yokobori, T. *et al.* Platin3 is a novel marker for circulating tumor cells undergoing the epithelial-mesenchymal transition and is associated with colorectal cancer prognosis. *Cancer research* **73**, 2059–2069, doi: 10.1158/0008-5472.CAN-12-0326 (2013).
76. Ueo, H. *et al.* Circulating tumour cell-derived platin3 is a novel marker for predicting long-term prognosis in patients with breast cancer. *British journal of cancer* **112**, 1519–1526, doi: 10.1038/bjc.2015.132 (2015).
77. Allison, K. H. & Sledge, G. W. Heterogeneity and cancer. *Oncology (Williston Park)* **28**, 772–778 (2014).
78. Zhang, C., Guan, Y., Sun, Y., Ai, D. & Guo, Q. Tumor heterogeneity and circulating tumor cells. *Cancer letters* **374**, 216–223, doi: 10.1016/j.canlet.2016.02.024 (2016).
79. Gorges, T. M. *et al.* Circulating tumour cells escape from EpCAM-based detection due to epithelial-to-mesenchymal transition. *BMC cancer* **12**, 178, doi: 10.1186/1471-2407-12-178 (2012).
80. Johnson, J. P., Kumar, P., Koulis, M., Patel, M. & Simin, K. Crucial and novel cancer drivers in a mouse model of triple-negative breast cancer. *Cancer genomics & proteomics* **11**, 115–126 (2014).
81. Hotz, B. *et al.* Epithelial to mesenchymal transition: expression of the regulators snail, slug, and twist in pancreatic cancer. *Clinical cancer research: an official journal of the American Association for Cancer Research* **13**, 4769–4776, doi: 10.1158/1078-0432.CCR-06-2926 (2007).
82. Rhim, A. D. *et al.* EMT and dissemination precede pancreatic tumor formation. *Cell* **148**, 349–361, doi: 10.1016/j.cell.2011.11.025 (2012).
83. Miller, A. J. & Mihm, M. C. Jr. Melanoma. *The New England journal of medicine* **355**, 51–65, doi: 10.1056/NEJMra052166 (2006).
84. Subramanian, A. *et al.* Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proceedings of the National Academy of Sciences of the United States of America* **102**, 15545–15550, doi: 10.1073/pnas.0506580102 (2005).
85. Carretero, J. *et al.* Integrative genomic and proteomic analyses identify targets for Lkb1-deficient metastatic lung tumors. *Cancer Cell* **17**, 547–559, doi: 10.1016/j.ccr.2010.04.026 (2010).
86. Baccelli, I. *et al.* Identification of a population of blood circulating tumor cells from breast cancer patients that initiates metastasis in a xenograft assay. *Nature biotechnology* **31**, 539–544, doi: 10.1038/nbt.2576 (2013).
87. Jolly, M. K. *et al.* Stability of the hybrid epithelial/mesenchymal phenotype. *Oncotarget*, doi: 10.18632/oncotarget.8166 (2016).
88. Shannon, P. *et al.* Cytoscape: a software environment for integrated models of biomolecular interaction networks. *Genome research* **13**, 2498–2504, doi: 10.1101/gr.1239303 (2003).
89. Sharma, S. *et al.* Secreted Protein Acidic and Rich in Cysteine (SPARC) Mediates Metastatic Dormancy of Prostate Cancer in the Bone. *J Biol Chem*, doi: 10.1074/jbc.M116.737379 (2016).
90. Esposito, M. & Kang, Y. Targeting tumor-stromal interactions in bone metastasis. *Pharmacol Ther* **141**, 222–233, doi: 10.1016/j.pharmthera.2013.10.006 (2014).
91. Tan, X. & Chen, M. MYLK and MYL9 expression in non-small cell lung cancer identified by bioinformatics analysis of public expression data. *Tumour Biol* **35**, 12189–12200, doi: 10.1007/s13277-014-2527-3 (2014).
92. Huan, J. *et al.* Overexpression of CD9 correlates with tumor stage and lymph node metastasis in esophageal squamous cell carcinoma. *Int J Clin Exp Pathol* **8**, 3054–3061 (2015).
93. Ji, C. *et al.* Deregulation of decorin and FHL1 are associated with esophageal squamous cell carcinoma progression and poor prognosis. *Int J Clin Exp Med* **8**, 20965–20970 (2015).
94. Xu, Y., Liu, Z. & Guo, K. Expression of FHL1 in gastric cancer tissue and its correlation with the invasion and metastasis of gastric cancer. *Mol Cell Biochem* **363**, 93–99, doi: 10.1007/s11010-011-1161-2 (2012).
95. Hamilton, G., Rath, B., Klameth, L. & Hochmair, M. J. Small cell lung cancer: Recruitment of macrophages by circulating tumor cells. *Oncoimmunology* **5**, e1093277, doi: 10.1080/2162402X.2015.1093277 (2016).
96. Kanehisa, M. & Goto, S. KEGG: kyoto encyclopedia of genes and genomes. *Nucleic acids research* **28**, 27–30 (2000).
97. Kanehisa, M., Sato, Y., Kawashima, M., Furumichi, M. & Tanabe, M. KEGG as a reference resource for gene and protein annotation. *Nucleic acids research* **44**, D457–462, doi: 10.1093/nar/gkv1070 (2016).

## Acknowledgements

We thank the Department of Biotechnology (DBT), Government of India for research support to the Institute of Bioinformatics. We thank the Council of Scientific and Industrial Research (CSIR), University Grants Commission (UGC), and Government of India and Infosys Foundation for financial support. PK is a recipient of the Ramanujan Fellowship awarded by the Department of Science and Technology (DST), Government of India, and AKM is a recipient of BINC Junior Research Fellowship from DBT, Government of India.

## Author Contributions

S.Y., S.J., S.S.M., A.K.M., H.G., J.P.T. and P.K. conceived and designed the study. S.Y., S.J. and D.S.N. were involved in curation of data. S.Y., S.J., S.S.M., A.K.M., A.C., H.G., R.B., A.R., J.P.T. and P.K. were involved in analysis and interpretation of data. T.Z.T. performed the EMT scoring. S.Y., S.J., J.P.T. and P.K. were involved in manuscript preparation.

## Additional Information

**Supplementary information** accompanies this paper at <http://www.nature.com/srep>

**Competing Interests:** The authors declare no competing financial interests.



**How to cite this article:** Yadavalli, S. *et al.* Data-Driven Discovery of Extravasation Pathway in Circulating Tumor Cells. *Sci. Rep.* **7**, 43710; doi: 10.1038/srep43710 (2017).

**Publisher's note:** Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



This work is licensed under a Creative Commons Attribution 4.0 International License. The images or other third party material in this article are included in the article's Creative Commons license, unless indicated otherwise in the credit line; if the material is not included under the Creative Commons license, users will need to obtain permission from the license holder to reproduce the material. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/>

© The Author(s) 2017